Cerdulatinib is an orally active kinase inhibitor that demonstrates activity against Syk and JAK with IC50 values of 32 nM, 12 nM, 6 nM and 8 nM for Syk, JAK1, JAK2 and JAK3, respectively. Cellular assays demonstrated specific inhibitory activity against signaling pathways that use Syk and JAK1/3. Limited inhibition of JAK2 was observed. Potent antitumor activity was observed in a subset of B-cell lymphoma cell lines.

KEYWORDS: Cerdulatinib | support | Syk/JAK inhibitor | PRT 062070 | PRT062070 | PRT-062070 | CAS [1198300-79-6] | CAS [1369761-01-2] | B-Cell Transformation | Spleen tyrosine kinase (Syk) | JAK | Inhibitor | Enzymes | B-cell lymphoma